UNLABELLED: Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from (18)F-FDG PET/CT are emerging prognostic biomarkers in various human cancers. This study examined the prognostic value of these metabolic tumor parameters measured by pretreatment (18)F-FDG PET/CT in patients with salivary gland carcinomas. METHODS: Forty-nine patients with intermediate- or high-grade salivary gland carcinomas who underwent definitive surgery with or without radiotherapy or chemoradiotherapy were evaluated preoperatively by (18)F-FDG PET/CT. Maximum standardized uptake values (SUV max), MTV, and TLG were measured for each patient. Univariate and multivariate analyses were used to identify clinicopathologic and imaging variables associated with progression-free survival (PFS) and overall survival (OS). Univariate analyses included the following variables: age, sex, pT and pN classifications, overall pTNM stage, histologic grade, resection margin, tumor lymphovascular invasion and perineural invasion, postoperative adjuvant therapy, gross total volume, SUV max, MTV, and TLG. RESULTS: The 3-y PFS and OS rates for all study patients were 66.9% and 81.6%, respectively. The median SUV max, MTV, and TLG were 5.1 (range, 1.7-21.5), 16.2 mL (1.0-115.1 mL), and 24.4 g (2.1-224.4 g), respectively. Univariate analyses showed that there were significant correlations between pT classification, pN classification, MTV, and TLG and both PFS and OS (P < 0.05). However, SUV max was not associated with either PFS (P = 0.111) or OS (P = 0.316). Multivariate analyses revealed that MTV (P = 0.011; hazard ratio, 11.50; 95% confidence interval, 1.45-91.01) and TLG (P = 0.038; hazard ratio, 3.55; 95% confidence interval, 1.07-11.76) were independent variables for PFS. CONCLUSION: Pretreatment values of MTV and TLG are independent prognostic factors in patients with intermediate or high-grade salivary gland carcinomas.
UNLABELLED: Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from (18)F-FDG PET/CT are emerging prognostic biomarkers in various humancancers. This study examined the prognostic value of these metabolic tumor parameters measured by pretreatment (18)F-FDG PET/CT in patients with salivary gland carcinomas. METHODS: Forty-nine patients with intermediate- or high-grade salivary gland carcinomas who underwent definitive surgery with or without radiotherapy or chemoradiotherapy were evaluated preoperatively by (18)F-FDG PET/CT. Maximum standardized uptake values (SUV max), MTV, and TLG were measured for each patient. Univariate and multivariate analyses were used to identify clinicopathologic and imaging variables associated with progression-free survival (PFS) and overall survival (OS). Univariate analyses included the following variables: age, sex, pT and pN classifications, overall pTNM stage, histologic grade, resection margin, tumor lymphovascular invasion and perineural invasion, postoperative adjuvant therapy, gross total volume, SUV max, MTV, and TLG. RESULTS: The 3-y PFS and OS rates for all study patients were 66.9% and 81.6%, respectively. The median SUV max, MTV, and TLG were 5.1 (range, 1.7-21.5), 16.2 mL (1.0-115.1 mL), and 24.4 g (2.1-224.4 g), respectively. Univariate analyses showed that there were significant correlations between pT classification, pN classification, MTV, and TLG and both PFS and OS (P < 0.05). However, SUV max was not associated with either PFS (P = 0.111) or OS (P = 0.316). Multivariate analyses revealed that MTV (P = 0.011; hazard ratio, 11.50; 95% confidence interval, 1.45-91.01) and TLG (P = 0.038; hazard ratio, 3.55; 95% confidence interval, 1.07-11.76) were independent variables for PFS. CONCLUSION: Pretreatment values of MTV and TLG are independent prognostic factors in patients with intermediate or high-grade salivary gland carcinomas.
Authors: Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang Journal: Eur J Nucl Med Mol Imaging Date: 2014-05-23 Impact factor: 9.236
Authors: Frank Hofheinz; Alexandr Lougovski; Klaus Zöphel; Maria Hentschel; Ingo G Steffen; Ivayla Apostolova; Florian Wedel; Ralph Buchert; Michael Baumann; Winfried Brenner; Jörg Kotzerke; Jörg van den Hoff Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-22 Impact factor: 9.236
Authors: S Temam; J Spicer; F Farzaneh; J C Soria; D Oppenheim; M McGurk; A Hollebecque; J Sarini; K Hussain; S Soehrman Brossard; L Manenti; S Evers; P Delmar; L Di Scala; C Mancao; F Feuerhake; L Andries; M G Ott; A Passioukov; J P Delord Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976
Authors: Arman Rahmim; C Ross Schmidtlein; Andrew Jackson; Sara Sheikhbahaei; Charles Marcus; Saeed Ashrafinia; Madjid Soltani; Rathan M Subramaniam Journal: Phys Med Biol Date: 2015-12-07 Impact factor: 3.609
Authors: Turki M Almuhaimid; Won Sub Lim; Jong-Lyel Roh; Jungsu S Oh; Jae Seung Kim; Soo-Jong Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim Journal: J Cancer Res Clin Oncol Date: 2018-10-06 Impact factor: 4.553
Authors: Yun Soo Park; Seok Mo Lee; Ji Sun Park; Sang Kyun Bae; Hye-Kyung Shim; Won-Sik Lee; Sang-Min Lee Journal: Nucl Med Mol Imaging Date: 2017-11-21